Bio-Rad Laboratories, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bio-Rad Laboratories, Inc.
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
Proposed rule issued in March 2010 requires ‘major statement’ on a drug’s side effects in ‘a clear, conspicuous, and neutral manner’ for TV and radio ads. Bill would mandate a final rule within six months.
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
- In Vitro Diagnostics
- Medical Devices
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
In Vitro Diagnostics
- Chemistry, Immunoassay
- Other Names / Subsidiaries
- AbD Serotec
- Celsee, Inc.
- Curiosity Diagnostics, Sp. Z. o. o.
- SafePath Laboratories